In the context of SARS-CoV-2, a phase 2 clinical trial has been completed looking at the efficacy of low-dose IL-2 in acute respiratory distress syndrome (ARDS) related to COVID-19 (NCT04357444). The gene discussed is IL2; the disease is acute respiratory distress syndrome.